European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach